Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Vaxcyte Inc’s stock clocked out at $89.97, up 3.85% from its previous closing price of $86.64. In other words, the price has increased by $3.85 from its previous closing price. On the day, 1.17 million shares were traded. PCVX stock price reached its highest trading level at $90.73 during the session, while it also had its lowest trading level at $83.96.
Ratios:
To gain a deeper understanding of PCVX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.88 and its Current Ratio is at 17.88. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 20, 2024, initiated with a Buy rating and assigned the stock a target price of $135.
On December 07, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $69.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when GUGGENHIME ANDREW sold 8,000 shares for $86.51 per share. The transaction valued at 692,101 led to the insider holds 109,491 shares of the business.
GUGGENHIME ANDREW bought 8,000 shares of PCVX for $688,480 on Jan 21 ’25. On Jan 15 ’25, another insider, Loxam Teri, who serves as the Director of the company, sold 6,250 shares for $85.11 each. As a result, the insider received 531,963 and left with 7,175 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCVX now has a Market Capitalization of 11214214144 and an Enterprise Value of 9061666816.
Stock Price History:
The Beta on a monthly basis for PCVX is 0.98, which has changed by 0.34722435 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, PCVX has reached a high of $121.06, while it has fallen to a 52-week low of $58.10. The 50-Day Moving Average of the stock is 1.49%, while the 200-Day Moving Average is calculated to be 4.15%.
Shares Statistics:
It appears that PCVX traded 1.29M shares on average per day over the past three months and 1505480 shares per day over the past ten days. A total of 124.43M shares are outstanding, with a floating share count of 120.32M. Insiders hold about 3.47% of the company’s shares, while institutions hold 107.45% stake in the company. Shares short for PCVX as of 1735603200 were 14322764 with a Short Ratio of 11.14, compared to 1732838400 on 11032601. Therefore, it implies a Short% of Shares Outstanding of 14322764 and a Short% of Float of 13.04.
Earnings Estimates
The stock of Vaxcyte Inc (PCVX) is currently drawing attention from 5.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$1.03, with high estimates of -$1.03 and low estimates of -$1.03.
Analysts are recommending an EPS of between -$3.69 and -$4.41 for the fiscal current year, implying an average EPS of -$3.91. EPS for the following year is -$4.35, with 6.0 analysts recommending between -$3.74 and -$4.99.
